Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Nov 17;128(20):2415-2422.
doi: 10.1182/blood-2016-05-717769. Epub 2016 Oct 4.

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Shaji K Kumar  1 , Betsy R LaPlant  2 , Craig B Reeder  3 , Vivek Roy  4 , Alese E Halvorson  2 , Francis Buadi  1 , Morie A Gertz  1 , P Leif Bergsagel  3 , Angela Dispenzieri  1 , Melanie A Thompson  1 , Jamie Crawley  1 , Prashant Kapoor  1 , Joseph Mikhael  3 , Keith Stewart  3 , Suzanne R Hayman  1 , Yi L Hwa  1 , Wilson Gonsalves  1 , Thomas E Witzig  1 , Sikander Ailawadhi  4 , David Dingli  1 , Ronald S Go  1 , Yi Lin  1 , Candido E Rivera  4 , S Vincent Rajkumar  1 , Martha Q Lacy  1
Affiliations
Clinical Trial

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Shaji K Kumar et al. Blood. .

Abstract

Proteasome inhibitors have become an integral part of myeloma therapy. Considerable efforts have gone into optimizing this therapeutic approach to obtain maximal proteasome inhibition with least toxicity. Ixazomib is the first oral proteasome inhibitor to enter the clinic and has been studied as a single agent as well as in various combinations. The current trial was designed to examine the efficacy and toxicity of combining 2 different doses of ixazomib (4 mg and 5.5 mg given weekly for 3 of 4 weeks) with 40 mg weekly of dexamethasone, in relapsed myeloma. Seventy patients were enrolled, 35 patients randomly assigned to each ixazomib dose. Overall, 30 (43%; 95% confidence interval, 31-55) of the patients achieved a confirmed partial response or better, with 31% achieving a response with 4 mg and 54% with 5.5 mg of ixazomib. The median event-free survival (EFS) for the entire study population was 8.4 months; 1-year overall survival was 96%. The EFS was 5.7 months for patients with prior bortezomib exposure and 11.0 months for bortezomib-naïve patients. A grade 3 or 4 adverse event considered at least possibly related to treatment was seen in 11 (32%) patients at 4 mg and in 21 (60%) at 5.5 mg. Dose reductions were more frequent with 5.5 mg dose. Overall, the ixazomib with dexamethasone has good efficacy in relapsed myeloma, is well-tolerated and with higher response rate at 5.5 mg, albeit with more toxicity. This study was registered at www.clinicaltrials.gov as #NCT01415882.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient disposition across the entire study for both treatment arms.
Figure 2.
Figure 2.
Waterfall plot showing the distribution of depth of response observed across both arms.
Figure 3.
Figure 3.
OS and EFS for the each of the study arms. (A) Arm B. (B) Arm C. NE, not evaluable.
Figure 4.
Figure 4.
Adverse Events. (A-B) Distribution of all grades of the most common toxicities considered at least possibly related to the drug administration; (A) Arm B, 4 mg and (B) Arm C, 5.5 mg. (C-D) Incidence of hematological toxicity across individual cycles, highlighting lack of any cumulative hematological toxicity; (C) Arm B, 4 mg and (D) Arm C, 5.5 mg.
Figure 5.
Figure 5.
Dosing of ixazomib during the first 12 cycles. (A) Arm B. (B) Arm C.
See this image and copyright information in PMC

References

    1. Moreau P, Richardson PG, Cavo M, et al. . Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947-959. - PMC - PubMed
    1. Kumar SK, Mikhael JR, Buadi FK, et al. . Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84(12):1095-1110. - PMC - PubMed
    1. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7(1):9-16. - PubMed
    1. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. . Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20(22):4420-4427. - PubMed
    1. Richardson PG, Sonneveld P, Schuster M, et al. . Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557-3560. - PubMed

Publication types

MeSH terms

Associated data